GlaxoSmithKline Reaches Plea Agreement Over Drug Labeling

GlaxoSmithKline Plc agreed to plead guilty and pay $3 billion to resolve criminal and civil allegations that it illegally promoted prescription drugs and failed to report safety data, the U.S. said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.